Abstract
Angiogenesis plays a vital role in the development of bladder cancer (BC). The Y-box-binding protein 1 (YB-1) is a well-known oncoprotein which is closely related to angiogenesis of tumors, but the relationship and mechanism of YB-1 and angiogenesis in BC remain unclear. Based on 56 clinical BC specimens, this study found that high expression of YB-1 samples demonstrated a higher expression of vascular endothelial growth factor A (VEGFA) than those of YB-1 low expression. Subsequently, the expression of YB-1 and miR-29b-3p was regulated in the BC cell lines where we noted that YB-1 promoted VEGFA expression by downregulating the expression of miR- 29b-3p. The ability of BC cells to induce angiogenesis decreased after YB-1 was knocked down. Moreover, the in vivo study further confirmed that YB-1 promotes angiogenesis in BC. Our findings enhance the understanding of how YB-1 promotes angiogenesis in BC and provide evidence for YB-1 as a therapeutic target of BC. Moreover, this may provide new inspiration for miRNAs replacement therapies.
Highlights
Bladder cancer (BC) is a prevalent malignant tumor threatening human health [1]
Results showed that the Y-box-binding protein 1 (YB-1) high expression group (YB-1 H) had higher vascular endothelial growth factor A (VEGFA) expression than that with YB-1 low expression (YB-1 L). e median of VEGFA IHC scores in YB1 H and YB-1 L was 18 and 15, respectively (Figure 1)
The expression of YB-1 was determined in EJ, UMUC3, SW780, and RT4 BC cell lines
Summary
Bladder cancer (BC) is a prevalent malignant tumor threatening human health [1]. Surgery is the primary treatment approach for BC, based on pathological stages, supplemented by chemotherapy or immunotherapy. This mode of therapy has the disadvantages of high cost and high recurrence [2]. Targeted therapy might provide a novel solution for the treatment of tumors, where oncogenes are important targets. Y-box-binding protein 1 (YB-1) is a well-known oncoprotein regulating tumor cell growth, invasion, metastasis, drug resistance, and angiogenesis [3, 4]. Our previous work revealed that elevated expression of YB-1 was significantly correlated with high clinical T stage and pathological T stage in BC [6]. Our previous work revealed that elevated expression of YB-1 was significantly correlated with high clinical T stage and pathological T stage in BC [6]. erefore, YB-1 is a potential molecular target for developing novel therapeutic strategies for BC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
